GNPX - Genprex achieves manufacturing milestone for immunogene therapy for upcoming lung cancer trials

Genprex ([[GNPX]] +0.4%) has passed the final release tests of scaled-up clinical grade production to supply REQORSA immunogene therapy for upcoming Acclaim-1 and Acclaim-2 trials in non-small cell lung cancer.The company recently announced the completion of the technology transfer of its manufacturing process for the production of REQORSA, as well as reported the completion of the manufacturing scale-up for the clinical-grade production of REQORSA, subject to final testing that was underway.This production run will supply the Company’s upcoming Acclaim-1 and Acclaim-2 trials that will evaluate REQORSA in combination with AstraZeneca's Tagrisso and with Merck's Keytruda, respectively, both of which are on track to be initiated in the first-half of 2021.

For further details see:

Genprex achieves manufacturing milestone for immunogene therapy for upcoming lung cancer trials